Research - Research groups - GA12 Severe Mental Illness-Health alerts

GA12 Severe Mental Illness-Health alerts

Over the past few years, our group has carried out its research activity as an associated group of IMIBIC. Prior to that, individual research initiatives were performed by our leading professionals, covering a range of fields and initiatives, as part of the Clinical Management Unit of the Mental Health Department.

The initial idea, and the one we wish to pursue, consists of deriving maximum benefit from the most outstanding features of Mental Health care in Andalusia. This network of community care provides us with first-rate accessibility and coordination with primary care and the addictions network, mental health teams made up of multi-disciplinary groups and the acute unit, which is an area of the general hospital. We believe that this organization gives us an excellent opportunity to deal directly with the real problems of the population we serve and to find practical answers which can be used immediately in this context.

Our action plan is known as -20+20, and we work to launch initiatives which address the severe problem of early mortality suffered by patients with a Serious Mental Illness (SMI). This population has 20 years’ lower life expectancy than the norm and the commonest causes of mortality are cardiovascular, respiratory and oncological problems.

Currently, our activity is mainly focused on initiatives linked to the main preventable factor, smoking. With the aim of recovering this population, which is somewhat isolated from the continued reduction of consumption observed in patients in the Western world, we strive for: greater awareness of the problem among the patient’s medical caregivers; the use of motivational tools to prepare the patient to try to change; and the study of the respiratory damage resulting from the severe comorbidity of SMI and smoking, as well as the chances of early prevention.

With this aim, our Clinical Unit has been carrying out research, training and diffusion activities in close collaboration with other units in Andalusia, as well as with other national groups which also research into the needs of SMI patients and which are also members of the CIBERSAM Group.

Funding from the Instituto de Salud Carlos III, together with alternative private resources, must be able to guarantee our activity and scientific production over the coming years.

Lines of Research

Premature mortality in Severe Mental Illness

Smoking, the main preventable risk factor

Development of tools to promote early diagnosis and mobilisation towards abstinence

Networks

CIBERSAM - CIBER on Mental Health (Group 05)

GETBA - Grupo para el Estudio del Trastorno bipolar en Andalucía

PAIDI CTS-550

Key Words

severe mental disorder
schizophrenia
bipolar disorder
tobacco cessation
mortality
readiness to change
chronic obstructive pulmonary disease
screening

Dr. Fernando Sarramea Crespo

Principal Investigator

Projects

PROJECTS IN 2023

Ongoing project

National

FERNANDO SARRAMEA CRESPO. Daño pulmonar en el Trastorno Mental Grave: factores de riesgo, evolución, y repercusión clínica, cognitiva y funcional. Funding Agency: INSTITUTO DE SALUD CARLOS III. Reference: PI20/01657

PROJECTS IN 2022

Ongoing project

National

FERNANDO SARRAMEA CRESPO; Daño pulmonar en el Trastorno Mental Grave: factores de riesgo, evolución, y repercusión clínica, cognitiva y funcional Funding Agency: INSTITUTO DE SALUD CARLOS III; Reference: PI20/01657

Publications

Publications in 2023

Jaen-Moreno MJ, Rico-Villademoros F, Ruiz-Rull C, Laguna-Munoz D, del Pozo GI, Sarramea F. A Systematic Review on the Association between Schizophrenia and Bipolar Disorder with Chronic Obstructive Pulmonary Disease. COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 2023. 31-43. DOI: 10.1080/15412555.2022.2154646. IF: 2,2 Q4 D

Publications in 2022

Garcia-Torres F, Jablonski MJ, Gomez-Solis A, Moriana JA, Jaen-Moreno M, Moreno-Diaz MJ, Aranda E. HEALTH PSYCHOLOGY REPORT. 2022. DOI: 10.5114/hpr.2021.111297

Garcia-Torres F, Tejero-Perea A, Gomez-Solis A, Castillo-Mayen R, Jaen-Moreno MJ, Luque B, Galvez-Lara M, Sanchez-Raya A, Jablonski M, Rodriguez-Alonso B, Aranda E. TRIALS. 2022. DOI: 10.1186/s13063-022-06731-w

Garcia-Torres F, Gomez-Solis A, Garcia SR, Castillo-Mayen R, Ruiz-Ruano VG, Moreno E, Moriana JA, Luque-Salas B, Jaen-Moreno MJ, Cuadrado-Hidalgo F, Galvez-Lara M, Jablonski M, Rodriguez-Alonso B, Aranda E. FRONTIERS IN PSYCHOLOGY. 2022. DOI: 10.3389/fpsyg.2022.871929

Alcala JA, Fontalba-Navas A, Company-Morales M, Romero-Guillena SL, Gutierrez-Higueras T, Gutierrez-Rojas L. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2022. DOI: 10.3390/ijerph19137633

Jimenez RAC, Moreno MJJ, del Rio LCYL, Fruet-Cardozo JV. MEDICINA DE FAMILIA-SEMERGEN. 2022. DOI: 10.1016/j.semerg.2022.02.002

Prados-Ojeda JL, Gordillo-Urbano RM, Carrillo-Perez T, Vazquez-Calvo A, Herrera-Cortes MA, Carreno-Ruiz MA, Font-Ugalde P. ARCHIVES OF SUICIDE RESEARCH. 2022. DOI: 10.1080/13811118.2021.1887023

Jaen-Moreno MJ, Garcia-Portilla MP, Sarramea F, Bascaran TB, Galvan G, Diaz-Mesa EM, Al-Halabi S, Elizagarate E, Martinez PAS, Bobes J, Garcia-Alvarez L. ADICCIONES. 2022. DOI: 10.20882/adicciones.1481.

Publications in 2021

Prados-Ojeda JL, Luque-Luque R, Gordillo-Urbano RM, Guler I, Lopez-Medina C, Collantes-Estevez E, Escudero-Contreras A. Assessment of Subclinical Psychotic Symptoms in Patients with Rheumatoid Arthritis and Spondyloarthritis. JOURNAL OF CLINICAL MEDICINE. 202 10(16):-. DOI: 10.3390/jcm1016346

IF: 4,241 Q1 D3

Jaen-Moreno MJ, Feu N, del Pozo GI, Gomez C, Carrion L, Chauca GM, Guler I, Montiel FJ, Sanchez MD, Alcala JA, Gutierrez-Rojas L, Molina V, Bobes J, Balanza-Martinez V, Ruiz-Rull C, Sarramea F. Chronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smoking. EUROPEAN PSYCHIATRY. 2021. 64(1):-. DOI: 10.1192/j.eurpsy.2021.1

IF: 5,361 Q1 D2

Garcia-Carmona M, Garcia-Torres F, Jablonski MJ, Solis AG, Jaen-Moreno MJ, Moriana JA, Moreno-Diaz MJ, Aranda E. The influence of family social support on quality of life of informal caregivers of cancer patients. NURSING OPEN. 202 8(6):3411-3419. DOI: 10.1002/nop2.887.

IF: 1,762 Q3

Caso JR, MacDowell KS, Gonzalez-Pinto A, Garcia S, De Diego-Adelino J, Carceller-Sindreu M, Sarramea F, Caballero-Villarraso J, Gracia-Garcia P, De la Camara C, Aguera L, Gomez-Lus ML, Alba C, Rodriguez JM, Leza JC. Gut microbiota, innate immune pathways, and inflammatory control mechanisms in patients with major depressive disorder. TRANSLATIONAL PSYCHIATRY. 2021. 11(1):-. DOI: 10.1038/s41398-021-01755-3.

IF: 6,222 Q1 D2

Cervera-Martinez J, Atienza-Carbonell B, Mota JC, Bobes-Bascaran T, Crespo-Facorro B, Esteban C, Garcia-Portilla MP, Gomes-da-Costa S, Gonzalez-Pinto A, Jaen-Moreno MJ, Sarramea F, Vieta E, Zorrilla I, Tabares-Seisdedos R, Kapczinski F, De Boni RB, Balanza-Martinez V. Lifestyle changes and mental health during the COVID-19 pandemic: A repeated, cross-sectional web survey. JOURNAL OF AFFECTIVE DISORDERS. 2021. 295():173-182. DOI: 10.1016/j.jad.2021.08.020.

IF: 4,839 Q1 D2

Giner-Murillo M, Atienza-Carbonell B, Cervera-Martinez J, Bobes-Bascaran T, Crespo-Facorro B, De Boni RB, Esteban C, Garcia-Portilla MP, Gomes-da-Costa S, Gonzalez-Pinto A, Jaen-Moreno MJ, Kapczinski F, Ponce-Mora A, Sarramea F, Tabares-Seisdedos R, Vieta E, Zorrilla I, Balanza-Martinez V. Lifestyle in Undergraduate Students and Demographically Matched Controls during the COVID-19 Pandemic in Spain. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2021. 18(15):-. DOI: 10.3390/ijerph18158133.

IF: 3,39 Q1 D3

Publications in 2020

Garcia-Torres F, Jablonski MJ, Solis AG, Jaen-Moreno MJ, Galvez-Lara M, Moriana JA, Moreno-Diaz MJ, Aranda E. Caregiver Burden Domains and Their Relationship with Anxiety and Depression in the First Six Months of Cancer Diagnosis. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2020. 17 (11):- DOI: 10.3390/ijerph17114101
IF: 2,849 Q: 1

Segura AG, Fatjo-Vilas M, Mitjans M, Garcia-Portilla MP, Garcia-Alvarez L, Sarramea F, Bobes-Bascaran T, de la Fuente-Tomas L, Iglesias AV, Martinez-Cao C, Gonzalez-Blanco L, Dal Santo F, Elizagarate E, Saiz PA, Fananas L, Bobes J, Arias B. Smoking cessation improves clinical outcome in severe mental disorders and is modulated by genetic variability at CHRNA5 gene. SCHIZOPHRENIA RESEARCH. 2020. 222 ():516-519 DOI: 10.1016/j.schres.2020.05.024
IF: 3,759 Q: 1

Garcia-Torres F, Jablonski MJ, Solis AG, Moriana JA, Jaen-Moreno MJ, Moreno-Diaz MJ, Aranda E. Social support as predictor of anxiety and depression in cancer caregivers six months after cancer diagnosis: A longitudinal study. JOURNAL OF CLINICAL NURSING. 2020. 29 (5-6):996-1002 DOI: 10.1111/jocn.15123
IF: 1,972 Q: 1

Fagiolini A, Alcala JA, Aubel T, Bienkiewicz W, Bogren MMK, Gago J, Cerveri G, Colla M, Sanchez FC, Cuomo A, Helge F, Iacoponi E, Karlsson PA, Peddu P, Pettorruso M, Pereira HJR, Scholin JS, Vernaleken IB. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. ANNALS OF GENERAL PSYCHIATRY. 2020. 19 (1):- DOI: 10.1186/s12991-020-00305-3
IF: 2,157 Q: 2

Publications in 2019

Carbone EA, Pugliese V, Bruni A, Aloi M, Calabro G, Jaen-Moreno MJ, Segura-Garcia C, De Fazio P; Adverse childhood experiences and clinical severity in bipolar disorder and schizophrenia: A transdiagnostic two-step cluster analysis. JOURNAL OF AFFECTIVE DISORDERS. 2019 Dec 1;259:104-111. doi: 10.1016/j.jad.2019.08.049.
IF: 4,084 D: 2 Q: 1

Sarramea F, Jaen-Moreno MJ, Balanza-Martinez V, Osuna MI, Alcala JA, Montiel FJ, Gomez C, Sanchez MD, Rico AB, Redondo-Ecija J, Gil S, Valdivia F, Caballero-Villarraso J, Gutierrez-Rojas L; Setting the stage to quit smoking in Bipolar Disorder patients: brief advice in clinical practice. ADICCIONES. 2019 Apr 1;31(2):136-146. doi: 10.20882/adicciones.1006.
IF: 3,167 Q: 1

Crespo FS, Jaen-Moreno MJ, Gutierrez-Rojas L, Balanza-Martinez V, Garcia-Alvarez L, Martinez PAS, Garcia-Portilla MP, Guler I, Bobes J; Readiness to Change Predicts Efficacy of Reduction among Smokers with Severe Mental Illness. EUROPEAN ADDICTION RESEARCH. 2019;25(5):256-262. doi: 10.1159/000500450.
IF: 2,653 Q: 2

Tamayo-Agudelo W, Jaen-Moreno MJ, Leon-Campos MO, Holguin-Lew J, Luque-Luque R, Bell V; Validation of the Spanish-language Cardiff Anomalous Perception Scale. PLOS ONE. 2019 Mar 6;14(3):e0213425. doi: 10.1371/journal.pone.0213425.
IF: 2,776 Q: 2

Crespo FS, Jaen-Moreno MJ, Gutierrez-Rojas L, Balanza-Martinez V, Garcia-Alvarez L, Martinez PAS, Garcia-Portilla MP, Guler I, Bobes J; Readiness to Change Predicts Efficacy of Reduction among Smokers with Severe Mental Illness. EUROPEAN ADDICTION RESEARCH. 2019;25(5):256-262. doi: 10.1159/000500450.
IF: 2,653 Q: 2

Jaen-Moreno MJ, Feu N, Redondo-Ecija J, Montiel FJ, Gomez C, del Pozo GI, Alcala JA, Gutierrez-Rojas L, Balanza-Martinez V, Chauca GM, Carrion L, Osuna MI, Sanchez MD, Caro I, Ayora M, Valdivia F, Lopez MS, Poyato JM, Sarramea F; Smoking cessation opportunities in severe mental illness (tobacco intensive motivational and estimate risk TIMER): study protocol for a randomized controlled trial. TRIALS. 2019 Jan 14;20(1):47. doi: 10.1186/s13063-018-3139-9.
IF: 1,975 Q: 3

Publications in 2018

Sarramea F, Jaen-Moreno MJ, Feu N, Redondo-Ecija J, Balanza-Martinez V, Gutierrez-Rojas L, Garcia-Portilla MP: Prepare the smoking cessation in severe mental illness: Early diagnosis and prevention opportunities. Rev Psiquiatr Salud Ment. Apr-Jun 2019;12(2):133-134. doi: 10.1016/j.rpsm.2018.08.001.

Clinical Research

Active in 2023

Ensayo clínico aleatorizado, multicéntrico, para evaluar la seguridad y tolerabilidad de clozapina vs tratamiento de práctica clínica habitual en psicosis resistente a tratamiento en personas adolescentes y adultos jóvenes con discapacidad intelectual.. IP: FERNANDO SARRAMEA CRESPO

Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de lclepertina una vez al día durante un periodo de tratamiento de 26 semanas en pacientes con esquizofrenia (CONNEX-2). IP: FERNANDO SARRAMEA CRESPO

Active in 2022

NALMEFENO PARA LA REDUCCIÓN DEL CONSUMO DE ALCOHOL EN EL TRASTORNO BIPOLAR EN COMORBILIDAD CON TRASTORNO POR CONSUMO DE ALCOHOL. PI: DR. JOSE ANGEL ALCALA PARTERA

NALMEFENO PARA LA REDUCCIÓN DEL CONSUMO DE ALCOHOL EN EL TRASTORNO BIPOLAR EN COMORBILIDAD CON TRASTORNO POR CONSUMO DE ALCOHOL. PI: DR. FERNANDO SARRAMEA CRESPO

Members

Principal Investigator
Fernando Sarramea Crespo

Researchers
Luis Gutiérrez Rojas
Rogelio Luque Luque

Post-Doctoral Researchers
José Ángel Alcalá Partera
María José Jaén Moreno
Antonio Jesús Moreno Campos
Juan Luis Prados Ojeda

Pre-Doctoral Researchers
Montserrat Alcántara García
Teresa Arribas Lozano
Francisca Blanco Quesada
Cristina Camacho Rodríguez
Ana Isabel Canalejo Rodríguez
Laura Carrión Expósito
Ana María Castellano Palma
Geli Marie Chauca Chauca
Gloria Isabel Del Pozo Seseña
María Teresa Espejo Obejo
Cristina Gómez Moreno
David Laguna Muñoz
María José Mellado Martínez
Francisco Javier Montiel López
María José Ortiz Alfaro
Maribel Osuna Carmona
Leonor Padilla Obrero
Inmaculada Polonio De Dios
Carmen Prada Carrasco
Justa Redondo Écija
María Luisa Rivera Hidalgo
Cristina Esther Ruiz Rull
Sonia Sánchez Gallardo
Araceli Sánchez Rodríguez
Francisca Valdivia Romero

Nurse
Maria Amparo Marco Feced
Inmaculada serrano Gómez
Maria Inmaculada Torrecillas Limonchi